The powerful combination of telemedicine and treatment for opioid dependence

0

The tech world is always on the lookout for a killer new app. The traditional definition1 A “killer app” is software or service so attractive that consumers will buy hardware to enjoy it, but increasingly, a killer app is defined by its ability to provide a service that was virtually impossible in the past. recent. For example, the late Steve Jobs launched the iPhone2 in 2007 saying, “The killer app is making calls!” ”

Of course, the former Apple boss focused on the traditional function of the phone at launch. Today, however, smartphones contribute to many aspects of our lives, including telemedicine and its potential to achieve positive results for patients facing opioid addiction. Effective treatments are more important than ever as opioid dependence and overdoses have increased during the COVID-19 pandemic.

A staggering 100,000 Americans have died of opioid overdoses in the past 12 months,3 a number that will undoubtedly continue to rise unless the necessary care reaches more people with drug addiction. Fortunately, modern advances in smartphone technology and video conferencing software pave the way for telemedicine to enter the fight against this scourge. In this emerging and unique application of telemedicine, it is crucial to address a central question: What treatment can be combined with medicine to provide the best results for patients?

An intensive study by QuickMD provided a clear answer to how cutting-edge innovation combined with MAT, or drug-assisted treatment, could solve the life-or-death problem of the disorder associated with the use of opioids.4 When the “M” in MAT refers to Suboxone – as is the case with QuickMD’s TeleMAT platform – providers can help alleviate withdrawal symptoms in patients while reducing the cravings patients feel for them. opioids. Suboxone (the most popular brand name of buprenorphine + naloxone)5 does not provide a high level, which means that patients can go about their daily business even during active treatment. As a result, our team developed TeleMAT based on three key factors:

Share.

Comments are closed.